The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published in Vaccine. The U.S. Food and Drug Administration approved PCV13 for use beginning in 2010 after a series of trials. These trials found that PCV13, which protects against a broader range of pneumococcal types than the previously used PCV7, did not increase the risk for any serious adverse events related to the vaccine...
-
Source: http://www.medicalnewstoday.com/releases/260915.php
--
Manage subscription | Powered by rssforward.com
24 May, 2013
-
Source: http://www.medicalnewstoday.com/releases/260915.php
--
Manage subscription | Powered by rssforward.com
Post a Comment